Receipt date: 07/21/2006

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. 0MB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Sub	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/596,348	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	June 9, 2006	
				First Named Inventor	Thomas I. F. H. Cremers,	
				Art Unit	N/A	
(Use as many sheets as necessary)			s necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	05432/0204244-US0	

			U.S. PA	TENT DOCUMENTS	, , , , , , , , , , , , , , , , , , , ,
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Г
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁹ (# known)				T°
	BA	EP-0687472	12-20-1995			Г
	BB	EP-0714663	06-05-1996			Г
	BC	WO-9728141	08-07-1997			П
	BD	WO-9603400	02-08-1996			Г
	BE	EP-0701819	03-20-1996			Г
	BF	WO-9913877	03-25-1999			Г

"EXAMINE: Initial II inference considered, whether or not clistion is in conformance with MEPE 900. Down like through cultion if not in conformance and not considered. Include copy of this from which execute considered. Include copy of this from which execute considered includes copy of the firm which execute considered includes copy of the firm which execute considered includes the execute considered includes an execution of the execution of t

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	CA	Artigas et al. Trends Pharmacol. Sci. 1993, 14, p 262-263			
	CB	Blier et al. J. Clin. Psycipharmacol. 1987, 7 suppl. 6, 24S-35S			
	cc	Invernizzi et al. Brain Res, 1992, 584, p 322-324			
	CD	Hjorth, S., J. Neurochem, 1993, 60, p 776-779			
	CE	Innis, R.B. et al. Eur. J. Pharmacol. 1987, 143, p 1095-204			
	CF	Gartside, S.E., Br. J. Pharmacol, 1995, 115, p 1064-1070			
	CG	Blier P. et al. Trends in Pharmacol. Science 1994, 15, 220			
	CH	Fernandez-Novoa L., Cacabelos R. Behav. Brain Res., vol 124 (2), pp. 213-233 (2001)			
	CI	Schlicker et al. Naunyn Schiedebergs Arch Pharmacol., col 377 (5): 588-590 (1988)			
	Cl	DiCarlo G., Ghi P., Orsetti M. Prog. Neuro-psychopharmacol. & Biol. Psychiat., vol 24, pp 275-284 (2000)			
	CK	Arrang J.M., Garbarg M., Schwartz J.C., Nature, vol 302, pp 832-837 (1983)			
	CL	Fink K., Schlicker E., Neise A., Gthert M., Naunyn Schiedebergss ARch Pharmacol., Vol. 342 (5): 513-519 (1990)	Γ		
	СМ	Wulff B., Shastrup S., Rimvall K., European Journal of Pharacology, vol. 453., pp 33-41 (2002)			

*EXAMINER: Initial if reference considered, whether or not disation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.R./

Examiner

/Savitha Rao/

Date

02/03/2009

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.